Top 10 Dermatology Articles of 2024

1. BREAKING NEWS: Benzene Found in Various Acne Products; Valisure Files Petition With FDA to Recall Treatments

High levels of the chemical benzene, which has been linked to cancer, were detected in numerous consumer acne products, including from major brands such as Proactiv, Clinique, and more.

2. FDA Approves Juvederm as the First and Only Hyaluronic Acid Dermal Filler for Use in Moderate to Severe Temple Hollowing

The approval also marks the first and only approved HA dermal filler approved in the US for use in the upper face.

3. Psoriasis Therapies in 2024 and Beyond

This article highlights recently approved psoriasis therapies that shaped the 2024 treatment landscape and provide some exciting updates in the psoriasis management market this coming year and beyond.

4. Hypochlorous Acid: Is It Just a Trend?

As someone who practices dermatology, it can often be difficult to determine if any of these new skin care trends are efficacious.

5. Dermatological Dilemma: Unmasking the Benzene Menace in Our Products

In our March publication, Winter Editor in Chief Christopher Bunick, MD, PhD, delved into the growing concern of benzene in personal care products. This commentary becomes all the more important in light of the findings of high levels of benzene in acne products.

6. Apogee Announces Positive Phase 1 Interim Data for APG777 in Atopic Dermatitis, Inflammatory Diseases

In addition to the announcement of positive data, Apogee said the trial has already exceeded its objectives ahead of schedule.

7. Updates on Benzene in Benzoyl Peroxide Products at AAD

Christopher Bunick, MD, PhD, presented updates and new data on the recent news of benzene found in benzoyl peroxide products.

8. Insights Into Clear Health’s Low-Dose Microdose Accutane Protocol For Mild Acne

Aaron Farberg, MD, discusses the low-dose, affordable Accutane treatment and Clear Health’s mission to improve patient access to affordable acne therapies.

9. New Hyperhidrosis Treatment Approval Expected in Mid-2024 Following FDA Delay

The novel topical anticholinergic/antimuscarinic will offer an additional strategy for the treatment of underarm hyperhidrosis.

10. La Roche-Posay Unveils New Molecule in Mela B3 Serum to Target Discoloration

Data on pigmentary disorders worldwide and clinical study results were presented at the IMCAS World Congress 2024 meeting.

What was your favorite news from 2023? Email us at DTEditor@mmhgroup.com.